RxDoctor Payments Data

Felix Gonzalez, MD

Internal Medicine · San Juan, PRNPI 1104057058

Payments from drug & device makers

$421in general payments, 2019–2025

Across 14 payments — averaging $30.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$110
  • Merck$82
  • Boehringer Ingelheim$55
  • Johnson & Johnson$50
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$43
  • E.r. Squibb & Sons, L.L.C.$40
  • plus $41 from 2 others

What the payments were for

  • Food & beverage$421100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$421 in reported general payments places this provider in the 40th percentile of 1,043 internal medicine providers in Puerto Rico.

See all internal medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$11,160
Medicare patients
22
Services billed
114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban53$36,136
JardianceEmpagliflozin20$17,081
BrilintaTicagrelor30$16,267
FarxigaDapagliflozin Propanediol21$14,550
XareltoRivaroxaban13$9,172
SynthroidLevothyroxine Sodium49$2,672
Famotidine197$1,765
Atorvastatin Calcium166$1,480
ClopidogrelClopidogrel Bisulfate139$1,293
LantusInsulin Glargine,hum.Rec.Anlog16$1,127
Metoprolol Succinate96$976
Losartan Potassium111$839
Irbesartan27$518
Pantoprazole Sodium58$449
Amiodarone Hcl12$385

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta, Farxiga$20$30,81751 claims
Boehringer IngelheimJardiance$55$17,08120 claims
Johnson & JohnsonXarelto$50$9,17213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,043 internal medicine providers in Puerto Rico.

Other internal medicine in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →